SCHEMBL26089334

SCHEMBL26089334

COc1ccc2nc(N3C[C@@H](C)N(C(=O)NC4CC5(C4)CN(Cc4ccccc4)C5)[C@@H](C)C3)cnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.44
CHRM4 P08173 5/20 0.41
HCRTR1 O43613 2/20 0.41
HCRTR2 O43614 2/20 0.41
CHRM2 P08172 4/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
CHRM5 P08912 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MCHR1 Q99705 1/20 0.39
GHSR Q92847 1/20 0.39
CACNA1G O43497 2/20 0.39
CACNA1H O95180 2/20 0.39
CACNA1I Q9P0X4 2/20 0.39
HPGDS O60760 1/20 0.38
KCNH2 Q12809 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26087163 1.00 HCAR2 (0.44) HCAR2CHRM4HCRTR1HCRTR2CHRM2
SCHEMBL26087104 0.90 CHRM2 (0.45) CHRM4CHRM2CHRM1CHRM3
SCHEMBL26090314 0.90 HCAR2 (0.54) HCAR2CHRM4HCRTR1HCRTR2CHRM2
SCHEMBL26090130 0.90 HCAR2 (0.54) HCAR2CHRM4HCRTR1HCRTR2CHRM2
SCHEMBL26089803 0.89 HCAR2 (0.46) HCAR2CHRM4CHRM2CHRM1CHRM3
SCHEMBL26087529 0.89 HCAR2 (0.46) HCAR2CHRM4CHRM2CHRM1CHRM3
SCHEMBL23744733 0.88 KDM4E (0.52) CHRM4CHRM2CHRM1CHRM3CHRM5
SCHEMBL23744528 0.88 KDM4E (0.52) CHRM4CHRM2CHRM1CHRM3CHRM5
SCHEMBL26087292 0.87 CHRM2 (0.46) HCAR2CHRM4CHRM2CHRM1CHRM3
SCHEMBL26087278 0.87 CHRM2 (0.46) HCAR2CHRM4CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP claimed
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 HCAR2 76/4885CHRM4 1/4885HCRTR1 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.